Hunan Jingfeng Pharmaceutical's restructuring plan has been approved by the court.
ST Jingfeng (000908.SZ) announcement, the company has received the Civil Judgment No. (2025) Xiang 07 Po 15 sent by the Intermediate People's Court of Changde City, Hunan Province. The Changde Intermediate Court approved the "Hunan Jingfeng Pharmaceutical Co., Ltd. restructuring plan" and terminated the company's restructuring process.
Hunan Jingfeng Pharmaceutical (000908.SZ) announced that the company has received the Civil Order No. (2025) Xiang 07 po 15 issued by the Intermediate People's Court of Changde City, Hunan Province. The Changde Intermediate Court has approved the "Hunan Jingfeng Pharmaceutical Co., Ltd. Restructuring Plan" and terminated the company's restructuring process.
Related Articles

JINKE SERVICES (09666) spent 291,100 Hong Kong dollars to repurchase 33,500 shares on February 3rd.

After nine months of sideways trading, TAL Education Group faces another round of executive "group selling." Despite strong performance, why doesn't TAL.US have a good stock price?

HOPE LIFE INT(01683): Chen Long appointed as co-chairman of the China region
JINKE SERVICES (09666) spent 291,100 Hong Kong dollars to repurchase 33,500 shares on February 3rd.

After nine months of sideways trading, TAL Education Group faces another round of executive "group selling." Despite strong performance, why doesn't TAL.US have a good stock price?

HOPE LIFE INT(01683): Chen Long appointed as co-chairman of the China region

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


